L. Moreau

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Joachim von Pawel, U. Gatzemeier, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2001 · 233 citations

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12

Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

M. Duruisseaux, Benjamin Besse, J. Cadranel et al. · Oncotarget · 2017 · 160 citations · Full text

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

Bruno Coudert, Laurent Arnould, L. Moreau et al. · Annals of Oncology · 2005 · 95 citations

Her2-overexpressing Stage Ii, Oncology, Breast Oncology +5

First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer

François‐Clément Bidard, Erica L. Mayer, Yeon Hee Park et al. · New England Journal of Medicine · 2025 · 73 citations